Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-24T23:55:45.577Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Sub-Groups of Multiple Sclerosis in Relation to HLA: DR Alleles as Possible Markers of Disease Progression

Published online by Cambridge University Press:  18 September 2015

Pierre Duquette ,
Francine Décary ,
Juliana Pleines ,
Denise Boivin ,
Gilles Lamoureux ,
James B.R. Cosgrove  and
Yves Lapierre
Pierre Duquette*
Affiliation:
Hôpital Notre-Dame, Montréal
Francine Décary
Affiliation:
Canadian Red Cross, Montréal
Juliana Pleines
Affiliation:
Hôpital Notre-Dame, Montréal
Denise Boivin
Affiliation:
Canadian Red Cross, Montréal
Gilles Lamoureux
Affiliation:
Institut Armand Frappier, Montréal
James B.R. Cosgrove
Affiliation:
Neurological Institute, Montréal
Yves Lapierre
Affiliation:
Neurological Institute, Montréal
*
Hôpital Notre Dame. 1560 Est Rue Sherbrooke. Montreal. Quebec. Canada H2L 4NI
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We have examined the distribution of HLA antigens in 70 multiple sclerosis (MS) patients divided in three groups defined according to clinical criteria: benign MS, severe MS, cerebellar MS. We have found a significant association between severe MS and HLA-DR2, and between benign MS of more than 15 years of evolution and HLA-DR3. We review previous work along the same line and conclude that the association of HLA antigens with “clinical subgroups of MS” could indicate a genetically based heterogeneity of the disease and offer help in establishing a prognosis.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 12 , Issue 2 , May 1985 , pp. 106 - 110
Copyright
Copyright © Canadian Neurological Sciences Federation 1985

References

Bell, DA.Rigley, R., Stiller, CR., Clark, WF., Harth, M., Ebers, GC. (1984) HLA antigens in systemic lupus erythematosus: relationship to disease severity, age at onset and sex. J of Rheumatology II: 475–479.Google ScholarPubMed
Cudworth, AG.Festenstein, H. (1978) HLA genetic heterogeneity in diabetes mellitus. British Medical Bulletin 34: 285–289.CrossRefGoogle ScholarPubMed
Delasnerie-Laupêtre, N., Suet-Hubert, C., Marcelli-Borg, A. (1982) Cerebrospinal fluid C2 and HLA system in multiple sclerosis. Tissue antigens 19: 79–84.CrossRefGoogle Scholar
Ebers, GC. (1983) Genetic factors in multiple sclerosis. Symposium on multiple sclerosis, Neurologic Clinics I, (ed) Saunders, W.B., vol. 3: 645–654.Google Scholar
Ebers, GC.Paty, DW., Morton, N. (1983) Segregation and linkage analysis of HLA typing in familial multiple sclerosis. Neurology 33 (suppl. 2): 180.Google Scholar
Ebers, GC.Paty, DW., Stiller, CR., Nelson, RF., Seland, TP., Larsen, B. (1982) HLA typing in multiple sclerosis sibling pairs. The Lancet 2: 88–90.CrossRefGoogle ScholarPubMed
Engel, AG. (1979) Handbook of Clinical Neurology, (eds) Vinken, P.J.Bruyn, G.W.Publ.: Elsevier North Holland. Myasthenia gravis, vol. 41 (part II): 95–146.Google Scholar
Engell, T.Raun, NE., Thomsen, M., Platz, P. (1982) HLA and heterogeneity of multiple sclerosis. Neurology 32: 1043–1046.CrossRefGoogle ScholarPubMed
Jersild, C.Fog, T., Hanalb, GS., Svejgoard, A., Thomsen, M., Dupont, B. (1973) HL-A determinants in multiple sclerosis with special reference to clinical course. Lancet (2): 1221–1224.CrossRefGoogle Scholar
Madigand, M.Oger, JJF., Fauchet, R.Sabouraud, O.Genetet, B. (1982) HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J of Neuro Sciences 53: 519–529.CrossRefGoogle ScholarPubMed
Poser, S.Ritter, G.Bauer, HJ.Grosse-Wilde, H.Kuwert, EM., Raun, NE. (1981) HLA antigens and the prognosis of multiple sclerosis. J of Neurology 225: 219–221.CrossRefGoogle ScholarPubMed
Raun, NE.Fog, T.Heltberg, A., Platz, P. (1980) Correlation of the course of MS and histocompatibility antigens in Progress in multiple sclerosis research, (eds) Bauer, HJ., Poser, S., Ritter, G.Publ Springer Verlag: 456–459.Google Scholar
Rose, AS.Ellison, GW., Myers, LW., Tourtelotte, WW. (1976) Criteria for the clinical diagnosis of multiple sclerosis. Neurology 26: 20–22.CrossRefGoogle ScholarPubMed
Stendhal-Brodin, L.Link, H., Moller, E., Norrby, E. (1979) Genetic basis of multiple sclerosis: HLA antigens, disease progression and oligoclonal IgG in CSF. Acta Neurol Scand 59: 297–308.CrossRefGoogle Scholar
Swinscow, TDV. (1978) Statistics at square one. Publ British Medical Association.Google Scholar
Terasaki, PI.Bernoco, D., Park, MS., Ozturk, G., Iwaki, Y. (1978) Microdroplet testing for HLA-A, B, C and D Antigens. Amer J of Clinical Pathology 69: 103–120.CrossRefGoogle Scholar
Terasaki, PI.McClelland, JD. (1964) Microdroplet assay of human serum cytotoxins. Nature 204: 998–1000.CrossRefGoogle ScholarPubMed